Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio Inc. has demonstrated strong momentum in its OviTex product line, with unit sales growing 22% in the latest quarter, while OviTex PRS unit sales saw a 3% increase, indicating robust demand for its soft-tissue reconstruction solutions. Despite Q3 revenue growth of 9% year-over-year falling short of expectations, the company is poised for a turnaround with improved sequential performance and strategic enhancements to its commercial leadership, projecting a more conservative yet attainable growth outlook. Additionally, TELA's recent financial maneuvers, including a $13 million equity raise and an upsized debt capacity, have significantly strengthened its balance sheet, extending its cash runway and providing the necessary resources to invest in sales force productivity and product development as it approaches 2026.

Bears say

TELA Bio Inc. has revised its full-year 2025 revenue guidance down to a minimum growth rate of 16%, equating to at least $80.4 million, which marks a decrease from the previously anticipated range of $85.0 million to $88.0 million and represents a substantial slowdown from earlier projections of 23-27% year-over-year growth. Additionally, the company's gross margin of 67.5% fell short of expectations by 200 basis points and decreased by 30 basis points year-over-year, coupled with an operating income miss of approximately $800,000 against previous estimates. This decline in financial outlook, alongside a significant drop in TELA's stock price of over 60% year-to-date, underscores concerns about the company's growth trajectory and operational efficiencies moving forward.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.